TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB clinical trials

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer

This study is testing a new medicine, TAK-280, for people with advanced cancer that can't be removed by surgery. It's an early-stage study looking at how safe the drug is, what side effects it might cause, and how the body handles it. We also want to see if it helps shrink tumours.